NCT05032118 (PENDULUM) is a Phase 2, PHASE3 clinical trial of Ketamine Hydrochloride in Subarachnoid Hemorrhage, Aneurysmal, sponsored by Jenna L Leclerc MD, PhD.

Who is sponsoring NCT05032118?

NCT05032118 is sponsored by Jenna L Leclerc MD, PhD.

What drugs are being tested in NCT05032118?

Interventions in NCT05032118: Ketamine Hydrochloride, Propofol.

What condition does NCT05032118 study?

NCT05032118 studies Subarachnoid Hemorrhage, Aneurysmal.

Is NCT05032118 still recruiting?

NCT05032118 is currently withdrawn. Last updated 1 May 2023.

Last reviewed 2023-05-01 · How we verify

NCT05032118: PENDULUM

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pilot Study of Ketamine Sedation for Aneurysmal Subarachnoid Hemorrhage

Withdrawn Phase 2, PHASE3 Last updated 1 May 2023

What this trial tests

Phase 2, PHASE3 trial testing Ketamine Hydrochloride in Subarachnoid Hemorrhage, Aneurysmal. Withdrawn.

Timeline

27 April 2023

Primary endpoint
27 April 2023

27 April 2023

Quick facts

Lead sponsor	Jenna L Leclerc MD, PhD
Phase	Phase 2, PHASE3
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	prevention
Start date	27 April 2023
Primary completion	27 April 2023
Estimated completion	27 April 2023

Drugs / interventions tested

Ketamine Hydrochloride — full drug profile →
Propofol (Propofol) — full drug profile →

Conditions studied

Subarachnoid Hemorrhage, Aneurysmal — all drugs for Subarachnoid Hemorrhage, Aneurysmal →

Sponsor

Jenna L Leclerc MD, PhD

Who can join

Adults 18 to 80, any sex, with Subarachnoid Hemorrhage, Aneurysmal. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Aneurysmal subarachnoid hemorrhage (aSAH) is bleeding into the space between the brain and the tissues that surround the brain as a result of a ruptured aneurysm and is a type of stroke associated with high morbidity and mortality. Those that survive the initial bleed are critically ill and require prolonged intensive care unit stays since they are at risk for a multitude of secondary insults that can further worsen functional outcomes. An especially feared secondary insult is delayed cerebral ischemia (DCI), which is a lack of blood flow to a particular portion of the brain that can result in an ischemic stroke and produce profound neurologic deficits. How DCI develops in some people after aSAH and not others is unknown, but many have hypothesized various mechanisms such as 1) cerebral vasospasm, a focal anatomic narrowing of the blood vessels in the brain that could decrease downstream blood flow, 2) abnormal electrical activity, and 3) microthrombi, or the formation of small blood clots. It is vitally important to identify a therapy that could protect the brain from these secondary insults that happen days after the initial brain bleed. Ketamine is a drug used in the majority of hospitals around the world for various indications, including general anesthesia, sedation, and for pain. Ketamine blocks a specific receptor that is present within the brain and in doing so could play a critical protective role against these secondary insults after aSAH by blocking the flow of dangerous chemicals. Ketamine may provide the following beneficial properties after aSAH: 1) pain control, 2) seizure prevention, 3) blood pressure support, 4) dilation of the brain blood vessels, 5) sedation, 6) anti-depressant, and 7) anti-inflammatory. This project is designed to test whether ketamine sedation in the intensive care unit after aneurysm repair provides better outcomes than the currently used sedation regimen.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Ketamine Hydrochloride

Trials testing the same drug.

NCT05603104 — Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First- · Phase 3 · recruiting
NCT06090422 — Ketamine for Combined Depression and Alcohol Use Disorder · Phase 1, PHASE2 · not yet recruiting
NCT06496750 — Ketamine for Methamphetamine Use Disorder · Phase 2 · recruiting
NCT05973851 — The Effect of a Six Week Intensified Pharmacological Treatment for Major Depressive Disorder Compared to Treatment as Us · Phase 3 · recruiting
NCT06366334 — Study of IV Ketamine for Emergency Department Treatment of Adolescent Suicidal Ideation · NA · recruiting

Other recruiting trials for Subarachnoid Hemorrhage, Aneurysmal

Currently open trials in the same condition.

NCT04696523 — Effect of Xenon on Brain Injury After Aneurysmal Subarachnoid Hemorrhage · Phase 2 · recruiting
NCT06819657 — Safety , Feasibility and Preliminary Efficacy of Remote Ischemic Conditioning in Patients With Aneurysmal Subarachnoid H · NA · recruiting
NCT06766422 — AI Models for Cerebral Aneurysms Segmentation, Detection and Stability Prediction · recruiting
NCT06906432 — Mechanisms of Brain-Heart Injury of Post-Intracranial Hemorrhage · recruiting
NCT06218654 — Hemodynamic Instability of Patient With Spontaneous Subarachnoid Hemorrhage · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05032118 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Jenna L Leclerc MD, PhD
Last refreshed: 1 May 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05032118.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing